After three failed CETP inhibitor programs over two decades, the European Commission has approved a fourth: obicetrapib, cleared last week as both a monotherapy (Ubeslo) and a fixed-dose combination with ezetimibe (Evlarco), with the combination delivering LDL-C reductions of roughly 41 percent at one year in the Phase 3 BROOKLYN trial. That number matters because it arrives in oral form, which is the practical gap PCSK9 inhibitors have struggled to close with patients who resist injections.
The approval covers adults with primary hypercholesterolaemia, including heterozygous familial and non-familial forms, and mixed dyslipidaemia. The supporting package spans three Phase 3 trials: BROADWAY, BROOKLYN, and TANDEM. The class carries heavy baggage. Torcetrapib’s ILLUMINATE trial was stopped in 2006 after 82 deaths in the treatment arm, and dalcetrapib and anacetrapib each failed on cardiovascular outcomes before reaching approval. Obicetrapib’s EC clearance means regulators were satisfied that its tolerability profile does not repeat those signals, though long-term cardiovascular outcomes data from a dedicated outcomes trial remain a question the approval does not answer.
The commercial picture sits with NewAmsterdam and Menarini Group, which hold European rights. Menarini’s distribution reach across European markets is the operational asset here: obicetrapib’s oral tablet format positions it where injectable PCSK9 inhibitors like alirocumab and evolocumab have faced adherence friction, and the fixed-dose Evlarco combination reduces pill burden for patients already on ezetimibe. Whether that convenience translates to formulary wins depends on pricing negotiations with European payers, which remain ongoing in most markets.
The trial that will define obicetrapib’s long-term standing is the cardiovascular outcomes study; until those data read out, prescribers treating high-risk patients will have to decide whether LDL-C reduction alone justifies the switch from therapies with established outcomes track records.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
